RxDoctor Payments Data

Adriana Ghisa, MD

Internal Medicine · Naugatuck, CTNPI 1467425371

Payments from drug & device makers

$828in general payments, 2019–2025

Across 46 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$160
  • Novo Nordisk$158
  • Astellas Pharma US Inc$60
  • Amarin Pharma, Inc.$56
  • Merck$53
  • AbbVie$48
  • plus $294 from 10 others

What the payments were for

  • Food & beverage$828100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$828 in reported general payments places this provider in the 75th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$99,175
Medicare patients
171
Services billed
1,149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide129$143,636
EliquisApixaban85$52,134
JanuviaSitagliptin Phosphate45$47,785
MounjaroTirzepatide33$45,276
LinzessLinaclotide60$37,600
FarxigaDapagliflozin Propanediol31$33,266
JardianceEmpagliflozin29$30,303
MyrbetriqMirabegron24$19,595
Breo ElliptaFluticasone/Vilanterol26$11,590
JanumetSitagliptin Phos/Metformin Hcl20$11,411
Advair HfaFluticasone Propion/Salmeterol14$9,430
DuleraMometasone/Formoterol28$9,274
Tresiba Flextouch U-100Insulin Degludec12$9,005
SymbicortBudesonide/Formoterol Fumarate21$8,599
TrintellixVortioxetine Hydrobromide12$5,773

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$158$143,636129 claims
MerckJanuvia, Janumet, Dulera$53$68,47093 claims
PfizerEliquis$34$52,13485 claims
Lilly USA, LLCMounjaro$16$45,27633 claims
AstraZenecaFarxiga, Symbicort$42$41,86552 claims
AbbVieLinzess, Synthroid$48$41,710105 claims
Boehringer IngelheimJardiance$37$30,30329 claims
Astellas Pharma US IncMyrbetriq$60$19,59524 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$20$5,77312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Naugatuck

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →